HIGHLIGHTS
- who: Eliana Shaul and collaborators from the University of Colorado Anschutz Medical Campus, United States have published the Article: Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate for clinical response and clinical remission in children with autoinflammatory VEO-IBD treated with canakinumab. Due to the retrospective design of this study, the varying cytokines were studied throughout the study window. This study shows that canakinumab is well tolerated and can be a good therapeutic option in this subset of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.